DK1943242T3 - Piperidin-4-yl-pyridazin-3-ylamin-derivater som hurtigt opløsende antagonister af dopamin-2-receptorer - Google Patents

Piperidin-4-yl-pyridazin-3-ylamin-derivater som hurtigt opløsende antagonister af dopamin-2-receptorer

Info

Publication number
DK1943242T3
DK1943242T3 DK06807495.4T DK06807495T DK1943242T3 DK 1943242 T3 DK1943242 T3 DK 1943242T3 DK 06807495 T DK06807495 T DK 06807495T DK 1943242 T3 DK1943242 T3 DK 1943242T3
Authority
DK
Denmark
Prior art keywords
pyridazin
dopamine
piperidin
antagonists
receptors
Prior art date
Application number
DK06807495.4T
Other languages
English (en)
Inventor
Bruyn Marcel Frans Leopold De
Gregor James Macdonald
Ludo Edmond Josephine Kennis
Xavier Jean Michel Langlois
Den Keybus Frans Alfons Maria Van
Roosbroeck Yves Emiel Maria Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK1943242T3 publication Critical patent/DK1943242T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK06807495.4T 2005-10-26 2006-10-24 Piperidin-4-yl-pyridazin-3-ylamin-derivater som hurtigt opløsende antagonister af dopamin-2-receptorer DK1943242T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05110028 2005-10-26
EP06100209 2006-01-10
EP06101545 2006-02-10
PCT/EP2006/067696 WO2007048779A1 (en) 2005-10-26 2006-10-24 Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists

Publications (1)

Publication Number Publication Date
DK1943242T3 true DK1943242T3 (da) 2011-04-26

Family

ID=35734993

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06807495.4T DK1943242T3 (da) 2005-10-26 2006-10-24 Piperidin-4-yl-pyridazin-3-ylamin-derivater som hurtigt opløsende antagonister af dopamin-2-receptorer

Country Status (34)

Country Link
US (3) US8940743B2 (da)
EP (1) EP1943242B1 (da)
JP (1) JP5140598B2 (da)
KR (1) KR101351910B1 (da)
CN (1) CN101291925B (da)
AP (1) AP2607A (da)
AR (1) AR058151A1 (da)
AT (1) ATE495167T1 (da)
AU (1) AU2006307930B2 (da)
BR (1) BRPI0617787A2 (da)
CA (1) CA2623160C (da)
CR (1) CR10020A (da)
CY (1) CY1111977T1 (da)
DE (1) DE602006019624D1 (da)
DK (1) DK1943242T3 (da)
EA (1) EA015681B1 (da)
EC (1) ECSP088396A (da)
ES (1) ES2359020T3 (da)
GT (1) GT200800033A (da)
HN (1) HN2008000646A (da)
HR (1) HRP20110226T1 (da)
IL (1) IL191016A (da)
JO (1) JO2769B1 (da)
MY (1) MY145609A (da)
NO (1) NO20082350L (da)
NZ (1) NZ566785A (da)
PL (1) PL1943242T3 (da)
PT (1) PT1943242E (da)
RS (1) RS51674B (da)
SI (1) SI1943242T1 (da)
TW (1) TWI399373B (da)
UA (1) UA94058C2 (da)
WO (1) WO2007048779A1 (da)
ZA (1) ZA200803668B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
WO2008128996A1 (en) 2007-04-23 2008-10-30 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
KR20100016498A (ko) * 2007-04-23 2010-02-12 얀센 파마슈티카 엔.브이. 속해리성 도파민 2 수용체 길항제로서의 피리딘 유도체
JP5431305B2 (ja) * 2007-04-23 2014-03-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 高速解離性ドパミン2受容体アンタゴニストとしての4−アルコキシピリダジン誘導体
WO2008145681A2 (en) * 2007-05-31 2008-12-04 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
EP2310374B1 (en) * 2008-07-03 2012-10-31 Janssen Pharmaceutica N.V. Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
EP2307374B1 (en) * 2008-07-31 2017-01-25 Janssen Pharmaceutica NV Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
DK2379525T3 (da) 2008-12-19 2015-10-19 Boehringer Ingelheim Int Cyklisk pyrimidin-4-carboxamider, som CCR2-receptor-antagonister til behandling af inflammation, astma og COPD
CA2778949C (en) 2009-10-30 2018-02-27 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors
WO2011073154A1 (en) 2009-12-17 2011-06-23 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists and uses thereof
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
RU2657540C2 (ru) 2012-06-26 2018-06-14 Янссен Фармацевтика Нв Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств
EP2869822B1 (en) 2012-07-09 2016-09-14 Janssen Pharmaceutica, N.V. Inhibitors of phosphodiesterase 10 enzyme
WO2017004537A1 (en) 2015-07-02 2017-01-05 Centrexion Therapeutics Corporation (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
US20180350708A1 (en) * 2017-06-06 2018-12-06 Powertech Technology Inc. Package structure and manufacturing method thereof
EP4574152A1 (en) 2023-12-22 2025-06-25 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Potassium channel activators for use in the treatment of epileptic disorders

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933823A (en) * 1971-03-29 1976-01-20 E. R. Squibb & Sons, Inc. Isoxazolopyridine ketone derivatives
DE2341965C3 (de) * 1973-08-20 1979-01-25 C.H. Boehringer Sohn, 6507 Ingelheim 4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen
US4197304A (en) * 1975-09-23 1980-04-08 Janssen Pharmaceutica N.V. N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides
NO147672C (no) 1975-09-23 1983-05-25 Janssen Pharmaceutica Nv Analogifremgangsmaate for fremstilling av n-aryl-n-(1-l1-4-piperidinyl)-arylacetamider
EG12406A (en) * 1976-08-12 1979-03-31 Janssen Pharmaceutica Nv Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides
DE3218482A1 (de) 1982-05-15 1983-11-17 Bayer Ag, 5090 Leverkusen Substituierte 5-trifluormethyl-1,3,4-thiadiazol-2-yloxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
ES8802151A1 (es) 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
PT93060B (pt) 1989-02-07 1995-12-29 Sanofi Sa Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem
US5461053A (en) * 1989-02-07 1995-10-24 Sanofi Pyridazine derivatives
GB9008850D0 (en) * 1990-04-19 1990-06-13 Janssen Pharmaceutica Nv Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones
GB9216298D0 (en) 1991-08-15 1992-09-16 Ici Plc Piperidine derivatives
EP0737189B1 (en) 1993-12-28 1999-07-28 PHARMACIA & UPJOHN COMPANY Heterocyclic compounds for the treatment of cns and cardiovascular disorders
DE4425145A1 (de) * 1994-07-15 1996-01-18 Basf Ag Verwendung von Thiazol- und Thiadiazolverbindungen
TW406075B (en) 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5753679A (en) 1995-05-10 1998-05-19 Hoffmann-La Roche Inc. Benzyl-piperidine derivatives
MY116093A (en) * 1996-02-26 2003-11-28 Upjohn Co Azolyl piperazinyl phenyl oxazolidinone antimicrobials
TW504510B (en) * 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
AU8457298A (en) * 1997-08-15 1999-03-08 Pfizer Products Inc. 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine D4 receptor
KR100261139B1 (ko) 1998-01-16 2000-08-01 황준수 신규한 알릴티오피리다진 유도체 및 그의 제조방법
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
WO2002068409A1 (en) 2001-02-23 2002-09-06 Merck & Co., Inc. N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
EP1443046B1 (en) 2001-10-09 2008-12-17 Kyorin Pharmaceutical Co., Ltd. Novel 4-(2furoyl)aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same
GB0127832D0 (en) 2001-11-20 2002-01-09 Jagotec Ag Method for the preparation of pharmaceutical nanosuspensions
AU2002360561A1 (en) 2001-12-11 2003-06-23 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
CA2474322A1 (en) 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
AU2003203148A1 (en) 2002-02-05 2003-09-02 High Point Pharmaceuticals, Llc Novel aryl- and heteroarylpiperazines
US20030236259A1 (en) 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
JP4467307B2 (ja) 2002-02-22 2010-05-26 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 5−ht受容体アンタゴニストとしてのピリジルスルホン誘導体
SE0201544D0 (sv) 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
JP3625214B2 (ja) * 2002-09-26 2005-03-02 株式会社マンダム 防腐殺菌剤並びに該防腐殺菌剤を配合した化粧料、医薬品及び食品
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
KR20050119652A (ko) 2003-03-24 2005-12-21 에프. 호프만-라 로슈 아게 역전사 효소 저해제로서의 벤질-피리다진온
BR0318298A (pt) 2003-05-07 2006-07-11 Ifac Gmbh & Co Kg composições para a liberação dirigida de fragráncias e aromas
BRPI0410239A (pt) 2003-05-08 2006-05-16 Kyorin Seiyaku Kk composto de 4-(2-furoil)aminopiperidina e medicamento
WO2005005779A2 (en) 2003-07-14 2005-01-20 Genesis Mining Technologies (Pty) Ltd Dual retention cutting arrangement
CA2532236C (en) 2003-07-29 2011-08-23 Novo Nordisk A/S Pyridazinyl- piperazines and their use as histamine h3 receptor ligands
EP3042895A1 (en) 2003-07-30 2016-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
JP2007501801A (ja) 2003-08-07 2007-02-01 日本たばこ産業株式会社 ピロロ[1,2−b]ピリダジン誘導体
WO2005046581A2 (en) 2003-10-24 2005-05-26 Cheng Tao M D P18 in stem cell manipulations
DE602005002251D1 (de) 2004-02-10 2007-10-11 Janssen Pharmaceutica Nv Pyridazinonharnstoffe als antagonisten von a4-integrinen
CN1934092A (zh) 2004-03-23 2007-03-21 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
CA2563963A1 (en) 2004-04-28 2005-11-10 Pfizer Inc. 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
CA2568524A1 (en) 2004-05-28 2005-12-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
JP4958786B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
CA2585172C (en) 2004-10-29 2014-08-12 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of ppar
EP2314320A2 (en) * 2005-04-05 2011-04-27 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Method for shielding functional sites or epitopes on proteins
JP2008546784A (ja) 2005-06-20 2008-12-25 シェーリング コーポレイション ヒスタミンh3アンタゴニストとして有用なピペリジン誘導体
JO2769B1 (en) * 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
KR101117931B1 (ko) 2006-08-15 2012-04-12 에프. 호프만-라 로슈 아게 페닐, 피리딘 및 퀴놀린 유도체
CA2606658A1 (en) * 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
TW200829566A (en) 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
JO2642B1 (en) * 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) * 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JP5431305B2 (ja) * 2007-04-23 2014-03-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 高速解離性ドパミン2受容体アンタゴニストとしての4−アルコキシピリダジン誘導体
WO2008128996A1 (en) * 2007-04-23 2008-10-30 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
KR20100016498A (ko) * 2007-04-23 2010-02-12 얀센 파마슈티카 엔.브이. 속해리성 도파민 2 수용체 길항제로서의 피리딘 유도체
AR068480A1 (es) * 2007-09-20 2009-11-18 Glaxo Group Ltd Compuesto de 4-heteroaril-piperidinil-n-substituido su uso para la preparacion de un medicamento util para el tratamiento de una afeccion en el que seria beneficioso el agonismo de un receptor muscarinico m1 y composicion farmaceutica que lo comprende
EP2310374B1 (en) * 2008-07-03 2012-10-31 Janssen Pharmaceutica N.V. Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists
EP2307374B1 (en) 2008-07-31 2017-01-25 Janssen Pharmaceutica NV Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists

Also Published As

Publication number Publication date
KR20080067658A (ko) 2008-07-21
GT200800033A (es) 2009-08-20
SI1943242T1 (sl) 2011-05-31
ES2359020T3 (es) 2011-05-17
ATE495167T1 (de) 2011-01-15
JO2769B1 (en) 2014-03-15
AP2008004441A0 (en) 2008-04-30
MY145609A (en) 2012-03-15
US9468640B2 (en) 2016-10-18
NO20082350L (no) 2008-07-01
EP1943242B1 (en) 2011-01-12
US20170022181A1 (en) 2017-01-26
AR058151A1 (es) 2008-01-23
US20080227791A1 (en) 2008-09-18
HRP20110226T1 (hr) 2011-05-31
NZ566785A (en) 2010-03-26
RS51674B (sr) 2011-10-31
AU2006307930B2 (en) 2011-10-06
DE602006019624D1 (de) 2011-02-24
CA2623160A1 (en) 2007-05-03
US9751860B2 (en) 2017-09-05
CN101291925A (zh) 2008-10-22
ZA200803668B (en) 2009-09-30
PL1943242T3 (pl) 2011-06-30
US8940743B2 (en) 2015-01-27
US20150141432A1 (en) 2015-05-21
PT1943242E (pt) 2011-04-06
TW200732321A (en) 2007-09-01
CA2623160C (en) 2013-10-15
HK1124317A1 (en) 2009-07-10
TWI399373B (zh) 2013-06-21
EA200801184A1 (ru) 2008-08-29
KR101351910B1 (ko) 2014-01-16
JP5140598B2 (ja) 2013-02-06
EP1943242A1 (en) 2008-07-16
EA015681B1 (ru) 2011-10-31
IL191016A (en) 2013-10-31
AP2607A (en) 2013-03-05
WO2007048779A1 (en) 2007-05-03
BRPI0617787A2 (pt) 2009-12-01
UA94058C2 (ru) 2011-04-11
JP2009514815A (ja) 2009-04-09
AU2006307930A1 (en) 2007-05-03
CY1111977T1 (el) 2015-11-04
ECSP088396A (es) 2008-05-30
HN2008000646A (es) 2011-02-16
CR10020A (es) 2009-01-16
CN101291925B (zh) 2013-04-10

Similar Documents

Publication Publication Date Title
DK1863818T3 (da) Acetylenyl-pyrazolo-pyrimidinderivater som mglur2-antagonister
DK2004654T3 (da) Pyrazolopyrimidin derivater til anvendelse som kinase antagonister
DK2094709T3 (da) Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister
DK1926722T3 (da) Substituerede benzimidazoler som kinaseinhibitorer
DK2069310T3 (da) Sulfonylpyrazolin-1-carboxamidin-derivater som 5-HT6-antagonister
DK2010498T3 (da) Syntese af acylaminoalkenylenamider, der kan anvendes som substans P-antagonister
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
HRP20151108T1 (xx) Antagonisti nogo-receptora
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
DK2029549T3 (da) Phenyl-pyrazol-derivater som ikke-steroide glucocoricoid-receptorligander
DK2102205T3 (da) Pyridopyrazinderivater anvendelige som herbicidale forbindelser
DK2170831T3 (da) Benzazepin-derivater egnede som vasopressin-antagonister
DK1856042T3 (da) Substituerede gamma-lactamer som terapeutiske midler
DK1963369T3 (da) Il-21-antagonister
DK2089367T3 (da) Pyrazolinforbindelser som mineralocorticoidreceptor-antagonister
DK2066628T3 (da) 2-Phenylindoler som antagonister af prostaglandin-D2-receptorer
DK1981875T3 (da) Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase
ATE415400T1 (de) Pyrazolopyridinderivate
ATE415385T1 (de) Hexafluorisopropanolsubstituierte etherderivate
BRPI0714764A2 (pt) Derivados substituídos de sulfonamida
DK1761519T3 (da) Indolderivater som histaminreceptorantagonister
DK2041128T3 (da) Substituerede gamma-lactamer som terapeutiske agenser
DK2076491T3 (da) Nye benzamidderivater som bradykininantagonister
DK1904477T3 (da) Indol-3-carbonyl-spiro-piperodom-derivater som V1A-receptorantagonister
DK1991529T3 (da) Substituerede arylsulfonamider som antivirale midler